UK gets closer to formulating wider societal benefit pricing mechanism
This article was originally published in Scrip
The UK is getting closer to coming up with a way to link the price of a new drug to the benefits it offers, not only to patients, but crucially to wider society. Although some pricing and reimbursement authorities look at a drug's wider societal benefits, no one has yet come up with a way of concretely linking them to a drug's price. So if the UK gets this right, whatever it comes up with could have a big impact in many other cash-strapped markets wrestling with limited drugs budgets and soaring medicine costs.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.